Saturday, March 18, 2017 12:28:37 PM
Peter,
I have tried to remain quiet over the last year or so even though I have been totally dissatisfied with the continual downward spiral of BioPath. You may recall that the last time I wrote to you I suggested that, for the sake of BioPath, you should retire. Since that time BioPath management has made several critical mistakes that have caused BioPath to lose total credibility in the market and which have significantly delayed the completion of the clinical trials as is evidenced by the current stock price and the inability to get any market traction. Meanwhile, you and the management board have paid yourselves handsomely as though you are a "real" company with excessive salary, bonuses and stock options, another horrible management mistake. May I remind you you are not a real company until you have product in the market place and are turning a profit! You are remiss in paying yourselves bonuses and stock options from shareholders investments. Your bonuses should ONLY be based on profitability of BioPath and the completion of critical timelines. In fact based upon current performance you should be taking a cut in salary as Tim Cook, Apple, did when he missed his performance goals!
Internet message boards have discussed that you have ignored the requests of biopharm heavyweights who have expressed an interest in participating with BioPath in helping the company complete clinical trials and in forming associations with major drug companies and the stock market. If this is the case you are neglecting your responsibilities to shareholders and may be putting yourself and the company in a position subject to legal action from shareholders for malfeasance!.
I implore you, Peter, to suck up your pride and allow some heavy weights in the industry (cancer biopharm and stock market) to become associated with BioPath. Please, please, please re-evaluate the members of Board of Directors and add members who have name recognition in the stock market and in pharmaceuticals but more importantly in getting things completed. Something has to happen to get this ship back into the channel and I feel that current management just keeps running her further aground!
I'm sorry for being so blunt but I feel that time is short for bringing this project to a long overdue conclusion. I'm guessing that if BioPath gets de-listed from Nasdaq your problems are only just beginning. That is my conclusion based upon over 30 years in the BioPharm industry.
Recent BPTH News
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress • GlobeNewswire Inc. • 05/24/2024 11:00:00 AM
- Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting • GlobeNewswire Inc. • 05/23/2024 09:00:00 PM
- U.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices Drop • IH Market News • 05/15/2024 11:50:05 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 11:10:29 AM
- Bio-Path Holdings Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/15/2024 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:10:34 PM
- Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024 • GlobeNewswire Inc. • 05/08/2024 11:00:00 AM
- Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/19/2024 04:14:04 PM
- Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • GlobeNewswire Inc. • 04/18/2024 05:57:59 PM
- Bio-Path Holdings Announces Successful Completion of Higher Dose Second Cohort in Phase 1/1b Clinical Trial of BP1002 in Refractory/Relapsed Acute Myeloid Leukemia (AML) Patients • GlobeNewswire Inc. • 04/18/2024 11:00:00 AM
- Bio-Path Holdings Expands Global Patent Portfolio • GlobeNewswire Inc. • 04/15/2024 11:00:00 AM
- Bio-Path Holdings Provides 2024 Clinical and Operational Update • GlobeNewswire Inc. • 04/02/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 11:00:34 AM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 03/08/2024 10:11:50 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 12:10:34 PM
- Bio-Path Holdings Reports Full Year 2023 Financial Results • GlobeNewswire Inc. • 03/08/2024 12:00:00 PM
- U.S. Index Futures Fluctuate Ahead of Key Jobs Report; Oil Prices Dip • IH Market News • 03/08/2024 11:22:25 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:21:27 PM
- Bio-Path Holdings to Announce Fourth Quarter and Full Year 2023 Financial Results on March 8, 2024 • GlobeNewswire Inc. • 03/01/2024 12:00:00 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/29/2024 11:00:30 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/23/2024 12:01:09 PM
- Bio-Path Holdings Announces 1-for-20 Reverse Stock Split • GlobeNewswire Inc. • 02/21/2024 12:00:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/02/2024 09:39:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 09:10:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:20:23 PM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM